The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Lonza

Monday Biotech Deal Review: September 28, 2009

Lots of deal news this week, including the Canadian action noted at the time: the iCo-CPDD deal and ethica’s in-license transaction.  Plus there was plenty of international excitement today (repentance notwithstanding) with Abbott’s $6.6 billion Solvay play and J&J’s new 18% stake in Crucell.  Keep reading for a securities-palooza and plenty more

Update Released by Patheon’s Special Commmittee

Patheon’s Special Committee provided an update today: “The Special Committee of Independent Directors of Patheon Inc. … today provided an update on its discussions with Lonza Group AG … regarding Lonza’s previously announced non-binding proposal to acquire all of the outstanding restricted voting shares of the Company at a price of US$3.55 per share. The [...]

Patheon Special Committee Responds to JLL Statements

Patheon’s special committee issued a press release today in which it: “commented … on the recent expiry of the unsuccessful bid by JLL … and recent statements by JLL regarding the previously announced proposal by Lonza … to acquire all of the outstanding Shares at a price of US$3.55 per share.”

Monday Deal Review: August 24, 2009

This week saw a few headline deals that we covered at the time, including the Vasogen-Cervus-IntelliPharmaCeutics deal, the move by Takeda Canada to take back ACTOS rights from Lilly, and the Lonza offer for Patheon, but other than that it seems like it was a quiet week everywhere. Still, check out some good stuff

Lonza Offers $460 Million for Patheon, JLL Rejects

JLL Partners’ long-standing bid for Patheon took a turn this morning as Lonza Group AG announced their own bid. Here’s Lonza’s press release. Here’s JLL’s response, rejecting the offer. Stay tuned…

Bristol-Myers Squibb Strikes $2.1 billion Deal for Medarex

Great news for Medarex shareholders from BMS’ $16/share offer yesterday, which clocks in at a 90% premium over Wednesday’s close.  Reports cite the value of ipilimumab, a late-stage cancer therapy being advanced as a new treatment for metastatic melanoma, as well as the value of Medarex’s transgenic mouse platform to make human antibodies. However, the [...]

Teva Decides Not to Wait for U.S. Biosimilars Legislation

In Beni’s post earlier this week on Biosimilars, he identified two major challenges to introducing follow-on biologics into the North American market: technical proficiency, and the absence of a regulatory regime. Based on the approval of Teva’s biosimilar version of Neupogen in the EU last September, Teva has evidently cleared the first hurdle (and their [...]

Follow

Get every new post delivered to your Inbox.

Join 84 other followers